Dyne Therapeutics, Inc. Operating Income Loss

• Dyne Therapeutics, Inc. showed a decrease of -36.1% in Operating Income Loss from 2024 to 2025.
• This data is from Dyne Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Dyne Therapeutics, Inc.'s Operating Income Loss has declined by 3,286.3%.
• Historical annual values: Fiscal year 2025: -$468.18 million | Fiscal year 2024: -$343.89 million | Fiscal year 2023: -$242.16 million | Fiscal year 2022: -$170.96 million | Fiscal year 2021: -$150.03 million | Fiscal year 2020: -$58.65 million | Fiscal year 2019: -$13.83 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026